AOL Money & Finance

sprycel posts

Feed

It's still a good time to buy BMY

I'm reiterating my Buy rating for Bristol-Myers Squibb (NYSE: BMY), first recommended on June 1, 2009 at a price of $20.11.

The low, single-digit revenue growth story remains intact for Bristol-Myers Squibb in FY2009. Hence, place BMY in the category of a get-ahead-of-the-pack play.

Continue reading It's still a good time to buy BMY

Time to scoop up some shares of Bristol-Myers Squibb

Readers of this space know that the investment bias is toward large-cap companies with demonstrated business models and who have a competitive advantage in established markets, preferably with a favorable, global trend as a support. And with that in mind, Bristol-Myers Squibb (NYSE: BMY) is worth a review.

In general, analysts forecast low, single-digit revenue growth for BMY in FY2009, weighed-down primarily by unfavorable foreign currency trends.

Continue reading Time to scoop up some shares of Bristol-Myers Squibb

Symbol Lookup
IndexesChangePrice
DJIA-154.4810,309.92
NASDAQ-37.612,138.44
S&P 500-19.141,091.49

Last updated: November 28, 2009: 09:57 AM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

WalletPop Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance